{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:31:40Z","timestamp":1772915500408,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1007\/s11102-005-1430-8","type":"journal-article","created":{"date-parts":[[2006,1,13]],"date-time":"2006-01-13T15:49:46Z","timestamp":1137167386000},"page":"265-269","source":"Crossref","is-referenced-by-count":18,"title":["PPAR-\u03b3 in Cushing's Disease"],"prefix":"10.1007","volume":"7","author":[{"given":"Anthony P.","family":"Heaney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,4]]},"reference":[{"key":"1430_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/ije\/29.2.197","volume":"29","author":"RM Merrill","year":"2000","unstructured":"Merrill RM, Feuer EJ, Capocaccia R, Mariotto A. Cancer prevalence estimates based on tumor registry data in the SEER program. Int J Epidemiol 2000;29:197\u2013207.","journal-title":"Int J Epidemiol"},{"key":"1430_CR2","unstructured":"Central Brain Tumor Registry of the United States (CBTRUS). http:\/\/www.cbtrus.org."},{"key":"1430_CR3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/neuonc\/3.3.141","volume":"3","author":"PJ Jukich","year":"2001","unstructured":"Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG. Trends in incidence of primary brain tumors in the United States, 1985\u20131994. Neuro-Oncology 2001;3:141\u2013151.","journal-title":"Neuro-Oncology"},{"key":"1430_CR4","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1210\/jcem.84.11.6202","volume":"84","author":"PU Freda","year":"1999","unstructured":"Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999;84:3859\u20133866.","journal-title":"J Clin Endocrinol Metab"},{"key":"1430_CR5","first-page":"526","volume":"85","author":"A Giustina","year":"2000","unstructured":"Giustina A, Barkan A, Casanueva FF, et\u00a0al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526\u2013529.","journal-title":"J Clin Endocrinol Metab"},{"key":"1430_CR6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1022308429992","volume":"5","author":"LK Niemann","year":"2002","unstructured":"Niemann LK. Medical Therapy of Cushing's Disease. Pituitary 2002;5:77\u201382.","journal-title":"Pituitary"},{"key":"1430_CR7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1749-6632.2002.tb04418.x","volume":"970","author":"D Morris","year":"2002","unstructured":"Morris D, Grossman A. The Medical Management of Cushing's Syndrome. Ann NY Acad Sci 2002;970:119\u2013133.","journal-title":"Ann NY Acad Sci"},{"key":"1430_CR8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrc1320","volume":"4","author":"AP Heaney","year":"2004","unstructured":"Heaney AP, Melmed S. Pituitary Tumors: Molecular Targets and New Medical Therapies. Nature Reviews Cancer 2004;4:285\u2013295.","journal-title":"Nature Reviews Cancer"},{"key":"1430_CR9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJM199503233321207","volume":"332","author":"DN Orth","year":"1995","unstructured":"Orth DN. Cushing's syndrome. N Engl J Med 1995;332:791\u2013803.","journal-title":"N Engl J Med"},{"key":"1430_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.2001.95.1.0001","volume":"95","author":"NE Simmons","year":"2001","unstructured":"Simmons NE, Alden TD, Thorner MO, Laws ER Jr. Serum cortisol response to transphenoidal surgery for Cushing disease. J Neurosurg 2001;95:1\u20138.","journal-title":"J Neurosurg"},{"key":"1430_CR11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7326\/0003-4819-109-6-487","volume":"109","author":"TJ Mampalam","year":"1988","unstructured":"Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing's disease: A report of 216 cases. Ann Intern Med 1988;109:487\u2013493.","journal-title":"Ann Intern Med"},{"key":"1430_CR12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s007010170077","volume":"143","author":"L Barbetta","year":"2001","unstructured":"Barbetta L, Dall'Asta C, Tomei G, Locatelli M, Giovanelli M, Ambrosi B. Assessment of cure and recurrence after pituitary surgery for Cushing's disease. Acta Neurochirurgica (Wien) 2001;143:477\u2013481.","journal-title":"Acta Neurochirurgica (Wien)"},{"key":"1430_CR13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2265.2002.01511.x","volume":"56","author":"DA Rees","year":"2002","unstructured":"Rees DA, Hanna FW, Davies JS, Miles RG, Vafidis J, Scanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single center using strict criteria for remission. Clin Endocrinol 2002;56:541\u2013551.","journal-title":"Clin Endocrinol"},{"key":"1430_CR14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","volume":"35","author":"JA Verlhest","year":"1991","unstructured":"Verlhest JA, Trainer PJ, Howlett TA, et\u00a0al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol 1991;35:169\u2013178.","journal-title":"Clin Endocrinol"},{"key":"1430_CR15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2265.1991.tb01737.x","volume":"34","author":"A Tabarin","year":"1991","unstructured":"Tabarin A, Navarranne A, Guerin J, Corcuff JB, Parmiex M, Roger P. Use of ketaconazole in the treatment of Cushing's diaease and ectopic ACTH syndrome. Clin Endocrinol 1991;34:63\u201369.","journal-title":"Clin Endocrinol"},{"key":"1430_CR16","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jcem-61-4-718","volume":"61","author":"N Sonino","year":"1985","unstructured":"Sonino N, Boscaro M, Merola G, Mantero F. Prolonged treatment of Cushing's disease by ketoconazole. J Clin Endocrinol Metab 1985;61:718\u2013722.","journal-title":"J Clin Endocrinol Metab"},{"key":"1430_CR17","first-page":"573","volume":"1","author":"DR McCance","year":"1981","unstructured":"McCance DR, Ritchie CM, Sheridan H, Atkinson AB. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1981;1:573.","journal-title":"Lancet"},{"key":"1430_CR18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","volume":"347","author":"I Issemann","year":"1990","unstructured":"Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645\u2013660.","journal-title":"Nature"},{"key":"1430_CR19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/358771a0","volume":"358","author":"SA Kliewer","year":"1992","unstructured":"Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992;358:771\u2013774.","journal-title":"Nature"},{"key":"1430_CR20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","volume":"47","author":"BM Spiegelman","year":"1998","unstructured":"Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507\u2013514.","journal-title":"Diabetes"},{"key":"1430_CR21","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nm784","volume":"11","author":"AP Heaney","year":"2002","unstructured":"Heaney AP, Fernando M, Yong W, Melmed S. Functional PPAR-\u03b3 receptor represents a novel therapeutic target in Cushing's disease. Nat Med 2002;11:1281\u20131287.","journal-title":"Nat Med"},{"key":"1430_CR22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI200316575","volume":"111","author":"AP Heaney","year":"2003","unstructured":"Heaney AP, Fernando M, Melmed S. PPAR-\u03b3 receptor ligands: A novel therapy for pituitary tumors. J Clin Invest 2003;111:1381\u20131388.","journal-title":"J Clin Invest"},{"key":"1430_CR23","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2337\/diab.45.12.1661","volume":"45","author":"AR Saltiel","year":"1996","unstructured":"Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661\u20131669.","journal-title":"Diabetes"},{"key":"1430_CR24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","volume":"391","author":"M Ricote","year":"1998","unstructured":"Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79\u201382.","journal-title":"Nature"},{"key":"1430_CR25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/2030","volume":"4","author":"P Sarraf","year":"1998","unstructured":"Sarraf P, Mueller E, Jones D, et\u00a0al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998;4:1046\u20131052.","journal-title":"Nat Med"},{"key":"1430_CR26","first-page":"1","volume":"9","author":"HP Koeffler","year":"2003","unstructured":"Koeffler HP. Peroxisome proliferator-activated receptor \u03b3 and cancers. Clin Cancer Res 2003;9:1\u20139.","journal-title":"Clin Cancer Res"},{"key":"1430_CR27","first-page":"51","volume":"26","author":"A Gruszka","year":"2005","unstructured":"Gruszka A, Kunert-Radek J, Pawlikowski M. Rosiglitazone, PPAR-gamma ligand decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro. Neuro Endocrinol Lett 2005;26:51\u201354.","journal-title":"Neuro Endocrinol Lett"},{"key":"1430_CR28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1500863","volume":"150","author":"F Bogazzi","year":"2004","unstructured":"Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, Viacava P, Cecchetti D, Acerbi G, Brogioni S, Cosci C, Gasperi M, Bartalena L, Martino E. PPAR-\u03b3 inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004;150:863\u2013875.","journal-title":"Eur J Endocrinol"},{"key":"1430_CR29","unstructured":"Alevizaki M, Philippou G, Zapanti L, Alevizaki CC, Anastasiou E, and Mavrikakis M. Significant improvement of recurrent pituitary-dependent Cushing's syndrome after administration of a PPAR-gamma agonist. The Endocrine Society's 86th Annual Meeting, New Orleans, 2004. P2-453 (abstract)."},{"key":"1430_CR30","first-page":"258","volume":"62","author":"SSA Hull","year":"2004","unstructured":"Hull SSA, Sheridan B, Atkinson AB. Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endocrinol 2004;62:258\u2013262.","journal-title":"Clin Endocrinol"},{"key":"1430_CR31","unstructured":"Heaney AP, Drange MR, Melmed S. Functional PPAR- receptor is a novel target for ACTH-secreting pituitary adenomas (Cushing's disease). The Endocrine Society's 85th Annual Meeting, Philadelphia 2003. OR7-4 (abstract)."},{"key":"1430_CR32","first-page":"1","volume":"151","author":"B Ambrosi","year":"2004","unstructured":"Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Pecoz P. Effects of chronic administration of PPAR-\u03b3 receptor ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004;151:1\u20137.","journal-title":"Eur J Endocrinol"},{"key":"1430_CR33","unstructured":"Zhu Y, Fernando M, Heaney AP. PPAR-\u03b3 binds a putative PPRE in the POMC promoter. The Endocrine Society's 86th Annual Meeting, New Orleans 2004. OR33-6 (abstract)."},{"key":"1430_CR34","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","volume":"90","author":"D Suri","year":"2005","unstructured":"Suri D, Weiss RE. Effect of Pioglitazone on ACTH and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005;90:1340\u20131346.","journal-title":"J Clin Endocrinol Metab"},{"key":"1430_CR35","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0149-2918(02)85040-8","volume":"24","author":"PJ Boyle","year":"2002","unstructured":"Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Therap 2002;24:378\u2013396.","journal-title":"Clin Therap"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-005-1430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-005-1430-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-005-1430-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T10:13:20Z","timestamp":1559556800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-005-1430-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s11102-005-1430-8","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}